Pfizer Inc.
Discovers, develops, manufactures and markets a broad portfolio of biopharmaceutical products including vaccines, oncology therapies, and treatments for cardiovascular, inflammation, rare disease and infectious conditions.
As of Sep 1, 2026
Summary
Pfizer Inc. is a multinational pharmaceutical and biotech company that develops, manufactures and distributes medicines and vaccines across multiple therapeutic areas. The stock is trading at $28.55 with a bullish technical lean, supported by solid recent momentum: it has returned 14.1% over the past month and 23.4% over the past year.
Price history
As of Sep 1, 2026
Performance
+0.32%
-0.07%
+14.06%
+13.70%
+20.58%
+23.39%
As of Sep 1, 2026
Technical indicators
- 69.1
- 0.02Bullish
- 50: 25.52 · 200: 25.38Bullish
- $25.80 / $28.58
Technical Bias
Bullish lean
Pfizer's technical setup is leaning bullish right now. The moving averages are aligned favourably with the price trading above both the 50-day and 200-day lines, while MACD momentum is positive; however, RSI at 69.1 reads neutral and suggests the stock is approaching overbought territory. This is a derived technical read, not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Sep 1, 2026
Fundamentals
- $162B
- 36.96
- $0.77
- 6.80%
- +2.6%
- $9.08B
- 0.28
- $22.03 – $29.09
- 6.15%
- Jul 24, 2026
- —
As of Sep 1, 2026
Latest news
As of Sep 1, 2026
MonkeyTrade's Take on Pfizer Inc.
Short-term outlook
Pfizer's short-term setup leans bullish, and with a 14.1% run over the past month plus MACD and both moving averages backing the move, the momentum looks fairly decisive. Support at $25.80 needs to hold to keep this intact, while a push through $28.58 would confirm further upside. That said, RSI at 69.1 shows the stock is getting stretched, so a pause or pullback toward support wouldn't be surprising before any next leg higher.
Medium-term outlook
Pfizer's numbers over the next few quarters point to a story of modest recovery rather than strong momentum: revenue growth of just 2.6% and a thin 6.8% profit margin sit awkwardly against a 36.96 P/E, suggesting the market is paying up for a turnaround that hasn't fully shown up in the fundamentals yet. Still, the bullish technical lean and a chunky 6.2% dividend yield tilt the medium-term balance in favour of the shares holding up. A meaningful acceleration in revenue growth would be the clearest signal the recovery is real.
Key risks
- Pfizer's profit margin of 6.8% is thin for a large pharmaceutical company, leaving little room to absorb cost pressures or pricing setbacks.
- A price-to-earnings ratio of 36.96 alongside modest revenue growth of 2.6% year-on-year suggests the stock's valuation may be running ahead of its actual sales momentum.
- Recent CFO turnover at Pfizer, noted alongside similar changes at AT&T and Caterpillar, can introduce uncertainty around financial strategy and reporting continuity.
- The stock is currently trading near the top of its 52-week range at $28.55 against a high of $29.09, which may limit near-term upside if growth doesn't accelerate to match investor expectations.
About Pfizer Inc.
Pfizer Inc. is a major pharmaceutical manufacturer listed on the NYSE under the ticker PFE, operating in the healthcare sector within the drug manufacturers - general industry. As one of the largest names in its field, Pfizer holds a market capitalisation of $162B, reflecting its scale and long-standing presence across global drug development and distribution.
Looking at the key figures, Pfizer trades on a price-to-earnings ratio of 36.96, which gives you a sense of how the market is currently pricing its earnings relative to its share price. The dividend yield stands at +6.2%, a figure income-focused investors often pay close attention to when weighing up a stock like this. Together, these metrics offer a snapshot of how Pfizer is currently valued and how it returns cash to shareholders.
How to trade Pfizer Inc.
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.